0001415889-24-010738.txt : 20240411
0001415889-24-010738.hdr.sgml : 20240411
20240411210101
ACCESSION NUMBER: 0001415889-24-010738
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240409
FILED AS OF DATE: 20240411
DATE AS OF CHANGE: 20240411
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Cui Xiangmin
CENTRAL INDEX KEY: 0001487815
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39351
FILM NUMBER: 24839812
MAIL ADDRESS:
STREET 1: NO. 14 EAST HUSHAN ROAD
STREET 2: TAI'AN CITY
CITY: SHANDONG
STATE: F4
ZIP: 000000
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Nuvation Bio Inc.
CENTRAL INDEX KEY: 0001811063
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 850862255
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 357 TEHAMA STREET, FLOOR 3
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94103
BUSINESS PHONE: (415) 754-3517
MAIL ADDRESS:
STREET 1: 357 TEHAMA STREET, FLOOR 3
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94103
FORMER COMPANY:
FORMER CONFORMED NAME: Panacea Acquisition Corp
DATE OF NAME CHANGE: 20200430
4
1
form4-04122024_010452.xml
X0508
4
2024-04-09
0001811063
Nuvation Bio Inc.
NUVB
0001487815
Cui Xiangmin
C/O NUVATION BIO INC.
1500 BROADWAY, SUITE 1401
NEW YORK
NY
10036
true
false
false
false
0
Class A Common Stock
2024-04-09
4
A
0
314106
A
314106
I
By Decheng Capital China Life Sciences USD Fund III, L.P.
Class A Common Stock
2024-04-09
4
A
0
1675236
A
1675236
I
By Decheng Capital Global Healthcare Fund (Master), LP
Class A Common Stock
2024-04-09
4
A
0
4183002
A
4183002
I
By Decheng Anbio Limited
Received pursuant to the Agreement and Plan of Merger and Reorganization, dated as of March 24, 2024, by and among Nuvation Bio Inc. (the "Issuer"), AnHeart Therapeutics Ltd. ("AnHeart"), Artemis Merger Sub I, Ltd., a wholly owned subsidiary of the Issuer ("Merger Sub I"), and Artemis Merger Sub II, Ltd., a wholly owned subsidiary of the Issuer ("Merger Sub II"), whereby Merger Sub I merged with and into AnHeart, with AnHeart surviving such merger as a direct, wholly owned subsidiary of the Issuer (the "First Merger"). Immediately following the First Merger, AnHeart, as the surviving company of the First Merger, merged with and into Merger Sub II, with Merger Sub II surviving such merger as a direct, wholly owned subsidiary of the Issuer (the "Second Merger" and,
collectively with the First Merger, as appropriate, the "Merger").
Received in exchange for 447,858 Series B Preferred shares of AnHeart in connection with the Merger (as described in footnote 1) on April 9, 2024.
These securities are owned directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). The Reporting Person is the manager of Decheng Capital Management III (Cayman), LLC, the general partner of Fund III. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein.
Received in exchange for 2,388,578 Series B Preferred shares of AnHeart in connection with the Merger (as described in footnote 1) on April 9, 2024.
These securities are owned directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healthcare"). The Reporting Person is the indirect managing member and ultimate beneficial owner of Decheng Capital Global Healthcare GP, LLC, the general partner of Healthcare. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein.
Received in exchange for 7,200,000 Series A Preferred shares, 685,714 Series A+ Preferred shares and 487,231 Series B Preferred shares of AnHeart in connection with the Merger (as described in footnote 1) on April 9, 2024.
These securities are owned directly by Decheng Anbio Limited ("SPV"). The Reporting Person is a director of SPV. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein.
/s/ Xiangmin Cui
2024-04-11